Omega Therapeutics (OMGA) Stock Forecast, Price Target & Predictions
OMGA Stock Forecast
Omega Therapeutics stock forecast is as follows: an average price target of $9.00 (represents a 765.38% upside from OMGA’s last price of $1.04) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
OMGA Price Target
OMGA Analyst Ratings
Omega Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Apr 03, 2024 | Edward Tenthoff | Piper Sandler | $9.00 | $3.01 | 199.00% | 765.38% |
Apr 01, 2024 | Keay Nakae | Loop Capital Markets | $7.00 | $3.65 | 91.78% | 573.08% |
Dec 08, 2022 | - | H.C. Wainwright | $11.00 | $6.30 | 74.60% | 957.69% |
Omega Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 2 |
Avg Price Target | - | - | $8.00 |
Last Closing Price | $1.04 | $1.04 | $1.04 |
Upside/Downside | -100.00% | -100.00% | 669.23% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Aug 15, 2024 | Wedbush | Buy | Buy | Hold |
Aug 15, 2024 | Raymond James | Underperform | Underperform | Hold |
Jun 18, 2024 | Piper Sandler | Underperform | Underperform | Hold |
Jun 18, 2024 | Raymond James | Buy | Buy | Hold |
Jun 18, 2024 | Raymond James | - | Outperform | Initialise |
May 07, 2024 | Chardan Capital | Underperform | Underperform | Hold |
May 07, 2024 | Piper Sandler | Buy | Buy | Hold |
Apr 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
Apr 01, 2024 | Chardan Capital | Buy | Buy | Hold |
Omega Therapeutics Financial Forecast
Omega Therapeutics Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | - | $831.00K | $759.00K | $516.00K | $735.00K | $595.00K | $476.00K | $268.00K |
Avg Forecast | $780.00K | $780.00K | $650.00K | $683.33K | $1.20M | $1.20M | $956.14K | $1.16M | $450.00K | $442.86K | $378.57K | $314.29K | $257.50K | $101.20K | $51.50K | $338.53K |
High Forecast | $780.00K | $780.00K | $650.00K | $683.33K | $1.20M | $2.30M | $956.21K | $1.16M | $483.87K | $442.86K | $378.57K | $314.29K | $257.50K | $101.20K | $51.50K | $406.23K |
Low Forecast | $780.00K | $780.00K | $650.00K | $683.33K | $1.20M | $481.77K | $956.07K | $1.16M | $411.29K | $442.86K | $378.57K | $314.29K | $257.50K | $101.20K | $51.50K | $270.82K |
# Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
Surprise % | - | - | - | - | - | - | - | - | - | 1.88% | 2.00% | 1.64% | 2.85% | 5.88% | 9.24% | 0.79% |
Omega Therapeutics EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
EBITDA | - | - | - | - | - | - | - | - | - | $-22.90M | $-30.84M | $-25.82M | $-30.97M | $-25.59M | $-25.45M | $-19.63M |
Avg Forecast | $-156.00K | $-156.00K | $-130.00K | $-136.67K | $-240.88K | $-240.88K | $-191.23K | $-232.86K | $-90.00K | $-88.57K | $-75.71K | $-62.86K | $-51.50K | $-20.24K | $-10.30K | $-24.80M |
High Forecast | $-156.00K | $-156.00K | $-130.00K | $-136.67K | $-240.88K | $-96.35K | $-191.21K | $-232.83K | $-82.26K | $-88.57K | $-75.71K | $-62.86K | $-51.50K | $-20.24K | $-10.30K | $-19.84M |
Low Forecast | $-156.00K | $-156.00K | $-130.00K | $-136.67K | $-240.88K | $-460.57K | $-191.24K | $-232.88K | $-96.77K | $-88.57K | $-75.71K | $-62.86K | $-51.50K | $-20.24K | $-10.30K | $-29.76M |
Surprise % | - | - | - | - | - | - | - | - | - | 258.58% | 407.32% | 410.74% | 601.31% | 1264.44% | 2470.82% | 0.79% |
Omega Therapeutics Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
Net Income | - | - | - | - | - | - | - | - | - | $-22.25M | $-29.69M | $-24.06M | $-30.68M | $-25.61M | $-25.97M | $-20.37M |
Avg Forecast | $-12.68M | $-12.46M | $-13.42M | $-12.78M | $-12.84M | $-15.44M | $-20.15M | $-18.36M | $-24.73M | $-29.15M | $-27.42M | $-32.38M | $-34.30M | $-32.68M | $-31.16M | $-25.47M |
High Forecast | $-12.68M | $-12.46M | $-13.42M | $-12.78M | $-12.84M | $-11.95M | $-20.15M | $-18.36M | $-24.19M | $-29.15M | $-27.42M | $-32.38M | $-34.30M | $-32.68M | $-31.16M | $-20.38M |
Low Forecast | $-12.68M | $-12.46M | $-13.42M | $-12.78M | $-12.84M | $-19.93M | $-20.15M | $-18.36M | $-25.80M | $-29.15M | $-27.42M | $-32.38M | $-34.30M | $-32.68M | $-31.16M | $-30.56M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.76% | 1.08% | 0.74% | 0.89% | 0.78% | 0.83% | 0.80% |
Omega Therapeutics SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
SG&A | - | - | - | - | - | - | - | - | - | $7.87M | $6.21M | $5.95M | $5.36M | $5.20M | $6.20M | $5.41M |
Avg Forecast | $20.92M | $20.92M | $17.43M | $18.33M | $32.30M | $32.30M | $25.64M | $31.23M | $12.07M | $11.88M | $10.15M | $8.43M | $6.91M | $2.71M | $1.38M | $9.08M |
High Forecast | $20.92M | $20.92M | $17.43M | $18.33M | $32.30M | $61.76M | $25.65M | $31.23M | $12.98M | $11.88M | $10.15M | $8.43M | $6.91M | $2.71M | $1.38M | $10.90M |
Low Forecast | $20.92M | $20.92M | $17.43M | $18.33M | $32.30M | $12.92M | $25.64M | $31.22M | $11.03M | $11.88M | $10.15M | $8.43M | $6.91M | $2.71M | $1.38M | $7.26M |
Surprise % | - | - | - | - | - | - | - | - | - | 0.66% | 0.61% | 0.71% | 0.78% | 1.92% | 4.49% | 0.60% |
Omega Therapeutics EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 16 | 8 | 18 |
EPS | - | - | - | - | - | - | - | - | - | $-0.40 | $-0.54 | $-0.48 | $-0.64 | $-0.54 | $-0.54 | $-0.43 |
Avg Forecast | $-0.23 | $-0.23 | $-0.24 | $-0.23 | $-0.23 | $-0.28 | $-0.37 | $-0.33 | $-0.45 | $-0.53 | $-0.50 | $-0.59 | $-0.62 | $-0.59 | $-0.56 | $-0.57 |
High Forecast | $-0.23 | $-0.23 | $-0.24 | $-0.23 | $-0.23 | $-0.22 | $-0.37 | $-0.33 | $-0.44 | $-0.53 | $-0.50 | $-0.59 | $-0.62 | $-0.59 | $-0.56 | $-0.57 |
Low Forecast | $-0.23 | $-0.23 | $-0.24 | $-0.23 | $-0.23 | $-0.36 | $-0.37 | $-0.33 | $-0.47 | $-0.53 | $-0.50 | $-0.59 | $-0.62 | $-0.59 | $-0.56 | $-0.57 |
Surprise % | - | - | - | - | - | - | - | - | - | 0.76% | 1.09% | 0.82% | 1.03% | 0.91% | 0.96% | 0.76% |
Omega Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
PMVP | PMV Pharmaceuticals | $1.64 | $24.75 | 1409.15% | Buy |
OMGA | Omega Therapeutics | $1.04 | $9.00 | 765.38% | Buy |
AVTE | Aerovate Therapeutics | $2.72 | $13.00 | 377.94% | Hold |
PEPG | PepGen | $6.79 | $29.50 | 334.46% | Buy |
CMPX | Compass Therapeutics | $1.70 | $5.00 | 194.12% | Buy |
LRMR | Larimar Therapeutics | $7.57 | $20.33 | 168.56% | Buy |
ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
OLMA | Olema Pharmaceuticals | $11.86 | $28.50 | 140.30% | Buy |
GPCR | Structure Therapeutics | $39.74 | $92.40 | 132.51% | Buy |
MLYS | Mineralys Therapeutics | $13.50 | $30.00 | 122.22% | Buy |
MLTX | MoonLake Immunotherapeutics | $46.40 | $79.33 | 70.97% | Buy |
PHVS | Pharvaris | $23.93 | $39.67 | 65.78% | Buy |
CNTA | Centessa Pharmaceuticals | $15.89 | $21.67 | 36.38% | Buy |
ELVN | Enliven Therapeutics | $27.65 | $35.50 | 28.39% | Buy |
OMGA Forecast FAQ
Is Omega Therapeutics a good buy?
Yes, according to 1 Wall Street analysts, Omega Therapeutics (OMGA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of OMGA's total ratings.
What is OMGA's price target?
Omega Therapeutics (OMGA) average price target is $9 with a range of $7 to $11, implying a 765.38% from its last price of $1.04. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Omega Therapeutics stock go up soon?
According to Wall Street analysts' prediction for OMGA stock, the company can go up by 765.38% (from the last price of $1.04 to the average price target of $9), up by 957.69% based on the highest stock price target, and up by 573.08% based on the lowest stock price target.
Can Omega Therapeutics stock reach $2?
OMGA's average twelve months analyst stock price target of $9 supports the claim that Omega Therapeutics can reach $2 in the near future.
What are Omega Therapeutics's analysts' financial forecasts?
Omega Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $4.53M (high $5.63M, low $3.81M), average EBITDA is $-906K (high $-761K, low $-1.126M), average net income is $-66.789M (high $-63.302M, low $-71.272M), average SG&A $121.48M (high $150.94M, low $102.09M), and average EPS is $-1.211 (high $-1.148, low $-1.292). OMGA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.89M (high $2.89M, low $2.89M), average EBITDA is $-579K (high $-579K, low $-579K), average net income is $-51.345M (high $-51.345M, low $-51.345M), average SG&A $77.6M (high $77.6M, low $77.6M), and average EPS is $-0.931 (high $-0.931, low $-0.931).
Did the OMGA's actual financial results beat the analysts' financial forecasts?
Based on Omega Therapeutics's last annual report (Dec 2023), the company's revenue was $3.09M, beating the average analysts forecast of $1.59M by 95.12%. Apple's EBITDA was $-100M, beating the average prediction of $-317K by 31514.01%. The company's net income was $-97.428M, missing the average estimation of $-114M by -14.29%. Apple's SG&A was $26.19M, missing the average forecast of $42.53M by -38.43%. Lastly, the company's EPS was $-1.8, missing the average prediction of $-2.061 by -12.67%. In terms of the last quarterly report (Sep 2023), Omega Therapeutics's revenue was $831K, beating the average analysts' forecast of $442.86K by 87.65%. The company's EBITDA was $-22.903M, beating the average prediction of $-88.571K by 25758.35%. Omega Therapeutics's net income was $-22.248M, missing the average estimation of $-29.151M by -23.68%. The company's SG&A was $7.87M, missing the average forecast of $11.88M by -33.75%. Lastly, the company's EPS was $-0.4, missing the average prediction of $-0.529 by -24.32%